Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that David Topper, ...

Arcutis Biotherapeutics, Inc.’s ARQT share price has dipped by 11.05%, which has investors questioning if this is right time ...

The sparsity of mid-to-late stage prospects in atopic dermatitis (AD, or eczema) – which has proved an especially challenging indication – plus some newsmaking fizzles in the space have caused ...

Raj Chovatiya, MD, PhD, MSCI, highlights promising research in atopic dermatitis focused on identifying patient subgroups for targeted treatments and achieving long-term remission.

An expert discusses the existing gaps in atopic dermatitis (AD) management, promising areas of research to address unmet needs, and key takeaways from the discussion for the managed care audience ...

A prospective registry study found a greater risk for infections associated with JAK inhibitors in adolescents and adults with moderate to severe atopic dermatitis compared with biologics.

Some topical cannabinoid therapies could be a safe and effective treatment for patients with atopic dermatitis (AD) says a ...

In this video, Peter Lio, MD, discussed updates on topical agents, biologics and drugs in the pipeline in atopic dermatitis from presentations at the American Academy of Dermatology meeting.

In this video, Raj Chovatiya, MD, PhD, discussed continued updates in the use of topical ruxolitinib in pediatric patients with atopic dermatitis.

A study found that children with early-onset atopic dermatitis have a higher risk of developing uveitis and should be closely ...